References
- Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2021 [Internet]. 2021. [cited 2022 Dec 9]. Available from: https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
- Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2011;12(1):7–11. doi: 10.1016/j.kisu.2021.11.003
- U.S. Renal Data System. 2022 USRDS annual data report: epidemiology of kidney disease in the United States [Internet]. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2022 [cited 2022 Dec 9]. Available from. https://usrds-adr.niddk.nih.gov/2022
- Centers for Disease Control and Prevention. Chronic kidney disease (CKD) surveillance system [Internet]. [cited 2023 Mar 7]. Available from: https://nccd.cdc.gov/ckd/FactorsOfInterest.aspx?type=Age
- Bansal N, Zelnick L, Bhat Z, et al. Burden and outcomes of heart failure hospitalizations in adults with chronic kidney disease. J Am Coll Cardiol. 2019;73(21):2691–2700. doi: 10.1016/j.jacc.2019.02.071
- Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606–617. doi: 10.1016/S2213-8587(19)30180-9
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389
- Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925
- Neuen BL, Ohkuma T, Neal B, et al. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program. J Am Soc Nephrol. 2019;30(11):2229–2242. doi: 10.1681/ASN.2019010064
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720
- Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi: 10.1056/NEJMoa1515920
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744
- The Empa-Kidney Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388(2):117–127.
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi: 10.1056/NEJMoa2107038
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816
- Jhund PS, Solomon SD, Docherty KF, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2021;143(4):298–309. doi: 10.1161/CIRCULATIONAHA.120.050391
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. doi: 10.1056/NEJMoa2022190
- AstraZeneca. Farxiga® (dapagliflozin) tablets, for oral use [prescribing information]. [Internet]. 2023. [cited 2023 Jul 18]. Available from: https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/0be9cb1b-3b33-41c7-bfc2-04c9f718e442/0be9cb1b-3b33-41c7-bfc2-04c9f718e442_viewable_rendition__v.pdf
- Boehringer Ingelheim. Jardiance® (empagliflozin tablets), for oral use [prescribing information] [Internet]. 2022. [cited 2022 Dec 9]. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf
- Janssen Pharmaceuticals. Invokana (canagliflozin) tablets, for oral use [prescribing information] [Internet]. 2022 [cited 2022 Dec 9]. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf
- Heerspink HJL, Jongs N, Chertow GM, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743–754. doi: 10.1016/S2213-8587(21)00242-4
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303
- Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–1098. doi: 10.1056/NEJMoa2206286
- Vaduganathan M, Claggett BL, Jhund P, et al. Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiol. 2022;7(12):1259–1263. doi: 10.1001/jamacardio.2022.3750
- Rossing P, Caramori ML, Chan JC, et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5):S1–S127. doi: 10.1016/j.kint.2022.06.008
- Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876–e894.
- ElSayed NA, Aleppo G, Aroda VR, et al. 11. Chronic kidney disease and risk management: standards of care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S191–S202. doi: 10.2337/dc23-S011
- Tisdale RL, Cusick MM, Aluri KZ, et al. Cost-effectiveness of dapagliflozin for non-diabetic chronic kidney disease. J Gen Intern Med. 2022;37(13):3380–3387. doi: 10.1007/s11606-021-07311-5
- McEwan P, Darlington O, Miller R, et al. Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022;17(12):1730–1741. doi: 10.2215/CJN.03790322
- IQVIA. IQVIA PharMetrics® Plus Fact Sheet [Internet]. 2020 [cited 2022 Dec 2]. Available from: https://www.greygreenmedia.com/app/uploads/sites/2/2020/09/IQVIA-PharMetrics-Plus-US-Fact-Sheet.pdf
- de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075–3090. doi: 10.2337/dci22-0027
- Evans M, Morgan AR, Whyte MB, et al. New therapeutic horizons in chronic kidney disease: the role of SGLT2 inhibitors in clinical practice. Drugs. 2022;82(2):97–108. doi: 10.1007/s40265-021-01655-2
- Tang H, Zhang X, Zhang J, et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia. 2016;59(12):2546–2551. doi: 10.1007/s00125-016-4101-6
- Yavin Y, Mansfield TA, Ptaszynska A, et al. Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis. Diabetes Ther. 2016;7(1):125–137. doi: 10.1007/s13300-015-0150-y